| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?
|
Quaquarini, E.
|
|
|
31 |
7 |
p. 958-959
|
artikel
|
| 2 |
A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer
|
Clemons, M.
|
|
|
31 |
7 |
p. 951-957
|
artikel
|
| 3 |
A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore
|
|
|
|
31 |
7 |
p. 840-843
|
artikel
|
| 4 |
Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?
|
Evesque, L.
|
|
|
31 |
7 |
p. 964-965
|
artikel
|
| 5 |
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
|
Zhang, L.
|
|
|
31 |
7 |
p. 894-901
|
artikel
|
| 6 |
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer † † Presented in part at the 2019 GU ASCO and ASCO Annual Meeting (Halabi S, Dutta S, Chi KN, et al. PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(suppl; abstr 5021). https://doi.org/10.1200/JCO.2019.37.15_suppl.5021.).
|
Halabi, S.
|
|
|
31 |
7 |
p. 930-941
|
artikel
|
| 7 |
COVID-19 infection in cancer patients: early observations and unanswered questions
|
Oh, W.K.
|
|
|
31 |
7 |
p. 838-839
|
artikel
|
| 8 |
Deep learning as a staging tool in gastric cancer
|
De Paepe, K.N.
|
|
|
31 |
7 |
p. 827-828
|
artikel
|
| 9 |
Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study
|
Dong, D.
|
|
|
31 |
7 |
p. 912-920
|
artikel
|
| 10 |
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
|
Ferris, R.L.
|
|
|
31 |
7 |
p. 942-950
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
31 |
7 |
p. iii
|
artikel
|
| 12 |
Extrachromosomal DNA—relieving heredity constraints, accelerating tumour evolution
|
Bailey, C.
|
|
|
31 |
7 |
p. 884-893
|
artikel
|
| 13 |
French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
|
Penel, N.
|
|
|
31 |
7 |
p. 965-966
|
artikel
|
| 14 |
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Approved by the ESMO Guidelines Committee: August 2007, last update March 2020. This publication supersedes the previously published version—Ann Oncol. 2012;23(suppl 7):vii124–vii130.
|
Pavel, M.
|
|
|
31 |
7 |
p. 844-860
|
artikel
|
| 15 |
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
|
Dunnett-Kane, V.
|
|
|
31 |
7 |
p. 873-883
|
artikel
|
| 16 |
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
|
Shim, J.H.
|
|
|
31 |
7 |
p. 902-911
|
artikel
|
| 17 |
Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1
|
Bayle, A.
|
|
|
31 |
7 |
p. 959-961
|
artikel
|
| 18 |
JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
|
Yoshino, T.
|
|
|
31 |
7 |
p. 861-872
|
artikel
|
| 19 |
Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil
|
Colloca, G.
|
|
|
31 |
7 |
p. 958
|
artikel
|
| 20 |
Personalized cancer supportive care in COVID-19 era
|
Lyman, G.H.
|
|
|
31 |
7 |
p. 835-837
|
artikel
|
| 21 |
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study † † Note: This work was previously presented in part at the 2019 American Society of Clinical Oncology meeting (Abstract 3513) and at the 2020 American Society of Clinical Oncology-GI meeting (Abstract 10).
|
Pagès, F.
|
|
|
31 |
7 |
p. 921-929
|
artikel
|
| 22 |
Re: Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
|
Mahal, B.A.
|
|
|
31 |
7 |
p. 829
|
artikel
|
| 23 |
Table of Contents
|
|
|
|
31 |
7 |
p. i-ii
|
artikel
|
| 24 |
Testing for COVID-19 in lung cancer patients
|
Passaro, A.
|
|
|
31 |
7 |
p. 832-834
|
artikel
|
| 25 |
The EAGLE study: two is not always better than one
|
Merlano, M.C.
|
|
|
31 |
7 |
p. 830-831
|
artikel
|
| 26 |
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
|
Michot, J.-M.
|
|
|
31 |
7 |
p. 961-964
|
artikel
|
Tijdschrift beschrijving